Latest news about Amrutanjan Health Care
Amrutanjan Health Care Gains 44,000 New Chemists, Targets 100,000 by September FY27
Amrutanjan Health Care
554.80
-19.05(-3.32%)
Company Performance:
View Company Insights1D-3.32%
1M+5.63%
6M-22.93%
1Y-22.45%
5Y-18.79%
More news about Amrutanjan Health Care
17Apr 26
Amrutanjan Health Care Rephrases Second Phase of Employee Stock Option Scheme
Amrutanjan Health Care Limited has rephrased the Second Phase ESOP 2 of its existing Employee Stock Option Scheme 2020, with approval from the Nomination and Remuneration Committee on April 17, 2026. The company informed stock exchanges about this development under SEBI regulations, maintaining compliance with listing obligations and disclosure requirements.
08Apr 26
Amrutanjan Health Care Submits Q4FY26 Compliance Certificate Under SEBI Regulations
Amrutanjan Health Care Limited submitted its Q4FY26 compliance certificate under SEBI (Depository Participants) Regulations on April 08, 2026. The certificate, issued by registrar Cameo Corporate Services Limited, confirms proper handling of dematerialised securities for the quarter ended 31/03/2026. The filing demonstrates the company's adherence to regulatory requirements for securities processing and depository participant regulations.
18Mar 26
Amrutanjan Health Care Receives Rs 24.28 Lakh GST Demand Order, Plans Appeal
Amrutanjan Health Care Limited received a Rs 24.28 lakh tax demand order under CGST/IGST Act 2017 from tax authorities on March 17, 2026, related to alleged input tax credit violations during 2020-21 to 2021-22. The company disagrees with the order citing proper compliance with GST law conditions and plans to file an appeal. Management believes the order will not have major financial implications on company operations.
18Mar 26
Amrutanjan Health Care Responds to NSE Surveillance Query on Court Order and News Article
Amrutanjan Health Care Limited responded to NSE surveillance queries regarding a news article and court order, clarifying that no negotiations were taking place and the news referred to an old 2005 case decided by Madras High Court. The company received the court order copy on 17 March 2026 and confirmed no material impact on business operations, with the matter already disclosed as contingent liability in annual reports.
03Feb 26
Amrutanjan Health Care Q3 Results: EBITDA Grows to ₹252M, Margin Declines YoY
Amrutanjan Health Care's Q3 results show EBITDA growth to ₹252M from ₹234M year-over-year, but EBITDA margin compressed to 17.85% from 19.02%. The company achieved revenue growth to ₹1.4B and maintained net profit at ₹195M, with board meeting held on February 3, 2026, for results review and interim dividend consideration.
11Nov 25
Amrutanjan Health Care Reports 7.08% Revenue Growth in Q2, Driven by Strong Pain Management Segment
Amrutanjan Health Care's Q2 results show a 7.08% YoY increase in revenue to Rs. 117.70 crores. Profit before tax grew by 20.51% to Rs. 19.21 crores, while profit after tax rose 14.23% to Rs. 15.94 crores. The pain management segment was a key growth driver, with the overall pain category growing 16%. The company plans to launch premium sanitary pads, revive the JIFFY brand, and commission a new sanitary napkin plant by late Q4. Management highlighted efforts to increase chemist channel reach and focus on market penetration in P1 markets and development in P2 markets.
10Nov 25
Amrutanjan Health Care Sets November 18, 2025 as Record Date for First Interim Dividend
Amrutanjan Health Care Limited has set November 18, 2025, as the record date for its first interim dividend of Re. 1/- per share for FY 2025-26. The company's board approved unaudited financial results for Q2 and H1 FY 2025-26, showing a 7.08% increase in revenue from operations and an 18.36% rise in profit after tax compared to the same quarter last year. The board meeting, held on November 10, 2025, lasted from 12:00 PM to 4:30 PM.
10Nov 25
Amrutanjan Health Care Reports Robust Q2 Performance with 18.4% Profit Growth
Amrutanjan Health Care Limited announced robust Q2 FY2025-26 results. Net profit increased by 18.4% to ₹139.60 crore, while revenue grew 7.1% to ₹1,177.00 crore. EBITDA rose 21.5% to ₹165.20 crore, with EBITDA margin expanding by 166 bps to 14.04%. The company declared a first interim dividend of ₹1 per share, with November 18, 2025, set as the record date.
12Aug 25
Amrutanjan Health Care Reports 80% Profit Surge, Sets AGM Date
Amrutanjan Health Care Limited announced Q1 FY2026 results with an 80% increase in profit after tax to ₹831.12 lakhs. Revenue from operations rose 12.3% to ₹9,404.57 lakhs. EPS improved to ₹2.87. OTC Products remained the largest revenue contributor. The company scheduled its 88th AGM for September 23, 2025, set September 16 as the record date, and appointed M/s. SPNP & Associates as Secretarial Auditor for five years.
15May 25
Amrutanjan Health Care Reports Strong Q4 Results, Announces Dividend
Amrutanjan Health Care's Q4 financial results show significant growth. Revenue increased by 6.30% to ₹1.35 billion, while net profit rose by 11.13% to ₹151.80 million. EBITDA improved to ₹177.00 million with a margin of 13.07%. The company also announced a final dividend of ₹2.60 per equity share, reflecting confidence in its financial position and commitment to shareholder value.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Lupin
Mankind Pharma
Zydus Life Science
Aurobindo Pharma
Laurus Labs
1,878.20
(+0.81%)
6,760.50
(-2.33%)
4,405.70
(+0.04%)
1,432.10
(-0.32%)
1,336.70
(+2.54%)
2,276.20
(+0.80%)
2,503.00
(+1.66%)
1,011.70
(+2.02%)
1,511.80
(+0.06%)
1,323.60
(+0.62%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
